Clinical trials: Vulvar Disease
Vulvodynia, Vestibulodynia
Effects of Flourish HEC on Localized Provoked Vulvodynia
This study is designed to determine whether improving the vaginal microbiome in women with localized provoked vulvodynia (LPV) may help improve pain better than routine care alone.
- Conditions
- Vulvodynia, Vestibulodynia, Vulvar Diseases, Vulvar Vestibulitis
- Trial name
- NCT05478746
- Testing
- BioNourish, a component of the Flourish HEC kit, Control - no intervention
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Vaginal Biome Science
Gynecologic Neoplasm, Brachytherapy
Using Reiki Therapy to Improve Symptoms Associated With Brachytherapy in Patients With Gynecological Malignancies
The goal of this open label, randomized, controlled clinical trial is to assess the benefits of providing Reiki therapy to subjects receiving their first brachytherapy treatment for gynecological malignancies.
- Conditions
- Gynecologic Neoplasm, Brachytherapy, Therapeutic Touch, Endometrial Cancer
- Trial name
- Reiki-Brachy (NCT05979610)
- Testing
- Reiki therapy
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- University of Utah
Vaginal Atrophy
Dehydroepiandrosterone (DHEA) Against Vaginal Atrophy
The purpose of this Phase III trial is to evaluate the efficacy of intravaginal dehydroepiandrosterone (DHEA) in postmenopausal women with vaginal atrophy.
- Trial name
- NCT01358760
- Testing
- DHEA
- Where
- 42 sites in United States, Canada
- Volunteers
- 450 people
- Sponsor
- EndoCeutics Inc.
Vulvovaginal Atrophy, Dyspareunia
Vulvoscopy Changes of the Vulva, Vestibule and Vagina With Daily Ospemifene in Women With Dyspareunia From VVA
This is an unblinded study to be conducted at a single research center, San Diego Sexual Medicine. Subjects meeting inclusion and exclusion criteria will receive 60 mg ospemifene daily for twenty weeks.
- Trial name
- NCT02784613
- Testing
- Ospemifene
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Sue Goldstein
Bone Cancer, Brain Cancer
Enhanced Assistance During Radiotherapy for Unmet Essential Needs
This is a prospective single-arm study of an enhanced assistance intervention for patients with unmet essential needs undergoing >10 fractions of radiotherapy comparing delay-free completion of radiotherapy in study participants…
- Conditions
- Bone Cancer, Brain Cancer, Colorectal Cancer, Esophagus Cancer
- Trial name
- EARN (NCT06582849)
- Testing
- Standard assistance, Enhanced assistance
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- Washington University School of Medicine
Lichen Sclerosus, Lichen Sclerosus et Atrophicus
Vulvar Scarring Grading Scale for Lichen Sclerosus
The study aims to validate a vulvar scarring grading scale for lichen sclerosus (LS).
- Trial name
- NCT02880904
- Testing
- Photography
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Northwestern University
Vulvar Cancers
A PHASE II, RANDOMIZED TRIAL TO ASSESS MAINTENANCE THERAPY WITH CEMIPLIMAB VERSUS BEST SUPPORTIVE CARE AFTER 1ST LINE PLATINUM-BASED CHEMOTHERAPY IN ADVANCED/RECURRENT VULVAR CANCER
This is a phase II, randomized study that will include 42 participants who have received 4 to 6 cycles of first-line platinum-based chemotherapy for advanced vulvar squamous cell carcinoma (SCC) not amenable to curative surgical…
- Trial name
- BRAVA VULVAR (NCT07101848)
- Testing
- Cemiplimab
- Where
- Brazil
- Volunteers
- 42 people
- Sponsor
- Hospital Israelita Albert Einstein
Vulvar Atrophy, Breast Cancer
Vaginal Prasterone In Vaginal Atrophy In Breast Cancer Survivors
VAGINAL PRASTERONE in the treatment of VAGINAL ATROPHY IN PATIENTS WITH BREAST CANCER TREATMENT WITH AROMATASE INHIBITORS (VIBRA STUDY)
- Conditions
- Vulvar Atrophy, Breast Cancer, Genitourinary Syndrome of Menopause
- Trial name
- VIBRA (NCT04705883)
- Testing
- Prasterone (DHEA), Micronized
- Where
- Spain
- Volunteers
- 10 people
- Sponsor
- Hospital Clinic of Barcelona
Vaginal Candidiasis
Postbiotic as Adjunct Treatment for Vaginal Candidiasis
This project aims to study the efficacy of oral administration of postbiotic at 1g/day as an adjunct treatment against vaginal candidiasis in women for 4-weeks compared to placebo.
- Trial name
- NCT06474247
- Testing
- Postbiotic
- Where
- 2 sites in India, Malaysia
- Volunteers
- 99 people
- Sponsor
- Min-Tze LIONG
Cervical Cancers, Vulvar Cancers
A Study of V503, a 9-valent Human Papillomavirus (9vHPV) Vaccine in Females 12-26 Years of Age Who Have Previously Received GARDASIL™ (V503-006)
This study will evaluate whether V503 (9vHPV vaccine), is well tolerated in girls and women between 12 and 26 years old who have previously been vaccinated with GARDASIL™.
- Conditions
- Cervical Cancers, Vulvar Cancers, Vaginal Cancers, Genital Warts
- Trial name
- NCT01047345
- Testing
- V503
- Volunteers
- 924 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Oropharyngeal Cancer, Neck Cancer
A Phase I/II Study of Combination Immunotherapy for Advanced Cancers Including HPV-Associated Malignancies, Small Bowel, and Colon Cancers
Background: Often, metastatic human papillomavirus (HPV) associated cancers cannot be cured. They also do not respond well to treatment. Some forms of colon cancer also have poor responses to treatment.
- Conditions
- Oropharyngeal Cancer, Neck Cancer, Human Papillomavirus, HPV
- Trial name
- NCT04708470
- Testing
- Bintrafusp Alfa, PDS01ADC, Entinostat
- Where
- United States
- Volunteers
- 55 people
- Sponsor
- National Cancer Institute (NCI)
Ovarian Cancer, Triple-Negative Breast Cancer
Prospective Biobanking Study in Cancer Patients Aiming at Better Understand the Link Between the Molecular Alterations of the Tumor Itself, Its Microenvironment and Immune Response (SCANDARE)
SCANDARE is a prospective biobanking study on tumor (+/- nodes), plasma and blood samples at different time points in ovarian, triple negative breast, Head and Neck Cancer, advanced stage treatment-naïve cervical or vulva cancer…
- Conditions
- Ovarian Cancer, Triple-Negative Breast Cancer, Head and Neck Cancer, Cervical Cancer
- Trial name
- SCANDARE (NCT03017573)
- Testing
- Tumor biopsies / Tumor surgery, Blood withdrawal
- Where
- 6 sites in France
- Volunteers
- 1,050 people
- Sponsor
- Institut Curie
Vestibulodynia (VBD) From at Least 6 Months
Ultrasound Evaluation and Vestibular Perception Thresholds Changes in Women Affected by Vestibulodynia (VBD) After One Cycle of Pixel CO2-Alma Fractionated Laser
Vestibulodynia (VBD), term revised by Consensus Terminology and Classification of Persistent Vulvar Pain and Vulvodynia in 2015, is a vulvar pain of at least 3 months' duration, without clear identifiable cause and localized at…
- Trial name
- NCT05156489
- Testing
- Fractionated Laser (Pixel CO2-Alma)
- Where
- Italy
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Dr. Filippo Murina
Vulvar Vestibulitis
"Vestibulitis Educational Seminar Trial" Study
The purpose of this study is to investigate the efficacy of an educational seminar series for women with vulvar vestibulitis syndrome (VVS).
- Trial name
- NCT00278850
- Testing
- Educational
- Where
- Canada
- Volunteers
- 500 people
- Sponsor
- University of British Columbia
Vulvovaginitis, Yeast Infection
Safety and Efficacy of Oral Encochleated Amphotericin B (CAMB/MAT2203) in the Treatment of Vulvovaginal Candidiasis (VVC)
This is a multi-center, randomized study to evaluate the safety, tolerability, and efficacy of 200 mg CAMB and 400 mg CAMB compared with a single 150 mg dose of fluconazole in the treatment of moderate to severe VVC.
- Conditions
- Vulvovaginitis, Yeast Infection, Yeast Infection Vaginal, Candidiasis, Vulvovaginal
- Trial name
- NCT02971007
- Testing
- Oral Encochleated Amphotericin B (CAMB), Fluconazole
- Where
- 23 sites in United States
- Volunteers
- 137 people
- Sponsor
- Matinas BioPharma Nanotechnologies, Inc.
Human Papillomavirus Infection
A Phase I Trial Evaluate the Safety and Tolerability Profile of HPV Vaccine
This study is to evaluate the safety and tolerability profile of Recombinant Nonavalent (Types 6/11/16/18/31/33/45/52/58) Human Papillomavirus (HPV) Vaccine (Escherichia Coli) in healthy women ages 18-45
- Trial name
- NCT05680454
- Testing
- Recombinant Nonavalent (Types 6/11/16/18/31/33/45/52/58) Human Papillomavirus (HPV) Vaccine (Escherichia Coli), Recombinant nonavalent Human Papillomavirus (Types 6,11,16,18,31,33,45,52,58) Vaccine
- Where
- China
- Volunteers
- 160 people, healthy volunteers welcome
- Sponsor
- Beijing Health Guard Biotechnology, Inc
Candidiasis, Vulvovaginal
Biweekly Long-term Occidiofungin Study for Suppression of Mycotic Recurrence
A Randomized, Double-Blind, Placebo-Controlled Phase 2a Study Evaluating the Safety, Tolerability, and Efficacy of OCF001 Intravaginal Gel in Women with Acute Vulvovaginal Candidiasis
- Trial name
- BLOSSOM (NCT07521137)
- Testing
- OCF001 Intravaginal Gel
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Sano Chemicals Inc
Vulvovaginal Candidiasis (VVC)
Evaluation of the Efficacy of a Probiotic Product as an Adjuvant Treatment for Vulvovaginal Candidiasis
Open-label, randomized clinical trial with a control group and a 4-week intervention period. The study will evaluate the efficacy of the probiotic supplement Bioithas WOMAN® as an adjunctive treatment in women with clinically…
- Trial name
- NCT07603895
- Testing
- Bioithas WOMAN®
- Where
- Spain
- Volunteers
- 60 people
- Sponsor
- Bioithas SL
Chronic Urogenital Pain
Life-Stress Interview for Women With Chronic Urogenital Pain Conditions
The goal of this study is to test the efficacy, feasibility, and acceptability of providing an experiential assessment interview that targets health, and emotional and stressful experiences in a tertiary care setting specializing…
- Trial name
- NCT02286115
- Testing
- Life-Stress Interview
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- Corewell Health East
Human Papillomavirus Infection
A Study to Evaluate the Immunogenicity and Safety of HPV Vaccine in Healthy Female Participants Aged 9-26 Years in China
The study is to evaluate immune response induced by 9-valent HPV study vaccine is non-inferior to those induced by GARDASIL® 9 administrated with 3-dose schedule in female participants aged 20-26 years in China, if the immune…
- Trial name
- NCT05662020
- Testing
- Recombinant Nonavalent (types 6/11/16/18/31/33/45/52/58) Human Papillomavirus (HPV) Vaccine (Escherichia coli), GARDASIL® 9
- Where
- China
- Volunteers
- 2,750 people, healthy volunteers welcome
- Sponsor
- Beijing Health Guard Biotechnology, Inc